Lv24
170 积分 2025-04-30 加入
Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies
15天前
已完结
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
1个月前
已完结
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
1个月前
已完结
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
1个月前
已完结
Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease
1个月前
已完结
ACG Clinical Guideline: Management of Crohn's Disease in Adults
1个月前
已完结
Overcoming the challenges of overtreating and undertreating inflammatory bowel disease
1个月前
已完结
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
1个月前
已完结
Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis
1个月前
已完结
Clinical outcome in hypertensive patients treated with amlodipine plus bisoprolol or plus valsartan
2个月前
已完结
皖公网安备34019202002308
